Statements (15)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:biotechnology
|
| gptkbp:acquiredBy |
gptkb:Novo_Nordisk
|
| gptkbp:acquisitionYear |
2020
|
| gptkbp:founded |
1986
|
| gptkbp:headquartersLocation |
gptkb:Roseland,_New_Jersey,_United_States
|
| https://www.w3.org/2000/01/rdf-schema#label |
Emisphere Technologies
|
| gptkbp:industry |
pharmaceuticals
|
| gptkbp:notableProduct |
gptkb:oral_semaglutide
|
| gptkbp:publiclyTraded |
yes
|
| gptkbp:specializesIn |
oral drug delivery
|
| gptkbp:stockSymbol |
gptkb:EMIS
|
| gptkbp:technology |
gptkb:Eligen_technology
|
| gptkbp:website |
https://www.emisphere.com/
|
| gptkbp:bfsParent |
gptkb:Novo_Nordisk
|
| gptkbp:bfsLayer |
6
|